MINNEAPOLIS, May 14 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin
Board: BTEL) announced results for its third quarter ended March 31, 2008
with net earnings of $99,000, or $0.03 per diluted share, on revenues of
$2,699,000. This compares to net earnings of $190,000, or $0.07 per diluted
share, on revenues of $2,990,000 for the third quarter of last year. For
the nine months ended March 31, 2008, Biotel had net earnings of $475,000,
or $0.17 per diluted share, on revenues of $8,309,000. This compares to net
earnings of $299,000, or $0.11 per share, on revenues of $8,119,000 for the
first nine months last year.
Highlights for the third quarter are as follows:
-- Sixth consecutive profitable quarter
-- Gross margin of 45.8%, up from 43.0% a year ago
-- Strong balance sheet with no long-term debt
-- Stockholders' equity of $4,445,000, up 13.0% year over year
"Biotel made good progress building for the future in the third
quarter, and the quarter's decrease in revenues had been preceded by some
very strong quarters," Biotel President and CEO Steve Springrose said.
"Sales of Holter devices, event recorders, liposuction and other medical
devices remain solid. The third quarter was diminished as some of our
customers deferred purchases in anticipation of important new products. We
launched a new Holter platform in March and are preparing to launch our
ER900 Wireless Event Recorder in our current quarter. The growth trend for
our Agility 24/7 cardiac monitoring services continued to rise in the third
quarter, contributing significantly to gross margin improvement. R&D
expenses were up significantly in the quarter as we invested in new
products and prototype parts. These expenses are essential to future
product competitiveness. In keeping with our long-term strategy, Biotel
serves as a development partner to medical corporations seeking new devices
and clinical research services."
'/>"/>
| SOURCE Biotel Inc. Copyright©2008 PR Newswire. All rights reserved |